Pro-resolving lipid mediator Lipoxin A4 attenuates neuro-inflammation by modulating T cell responses and modifies the spinal cord lipidome.
Multiple sclerosis (MS) is the most common chronic inflammatory disorder of the central nervous system (CNS), characterized by blood-brain barrier disruption, immune cell infiltration into the CNS, demyelination and neurodegeneration. The majority of the current therapies consists of immunosuppressive or anti-inflammatory agents, which are effective in early stages of the disease, but often results in severe side effects and eventually fail to prevent disease progression. Therefore, there is an urgent need to develop alternative approaches allowing not only to interfere with chronic neuro-inflammation, but also to promote local tissue recovery and subsequent homeostasis.
